NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $707,400.00 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock traded up $0.69 during trading on Tuesday, reaching $17.29. The company had a trading volume of 454,562 shares, compared to its average volume of 258,218. The firm’s fifty day moving average is $16.54 and its 200-day moving average is $18.96. NewAmsterdam Pharma has a fifty-two week low of $5.63 and a fifty-two week high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.08. The firm had revenue of $2.28 million for the quarter, compared to the consensus estimate of $2.20 million. Equities analysts forecast that NewAmsterdam Pharma will post -2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NAMS has been the subject of a number of research reports. Needham & Company LLC assumed coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, August 28th. They set a “buy” rating and a $36.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $33.80.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently bought and sold shares of the business. Millennium Management LLC grew its position in NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after acquiring an additional 217,902 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at about $22,015,000. Deerfield Management Company L.P. Series C raised its stake in shares of NewAmsterdam Pharma by 30.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after acquiring an additional 202,250 shares in the last quarter. Artal Group S.A. acquired a new position in NewAmsterdam Pharma during the first quarter valued at approximately $18,920,000. Finally, Janus Henderson Group PLC acquired a new position in NewAmsterdam Pharma in the 1st quarter valued at $15,018,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.